Notable updates, news, or analysts actions from our trading lists followed by 'Our Take'.Iovance Biotherapeutics upgraded to Buy from Neutral at H.C. Wainwright H.C. Wainwright analyst Joseph Pantginis upgraded Iovance Biotherapeutics to Buy from Neutral with a $50 price target. The recent weakness in the shares creates a "compelling entry point" for investors ahead of the 2021 planned application filings for the company's TILs in both melanoma and cervical cancer, Pantginis tells investors in a research note. The analyst also expects to receive incremental clinical data during the year.Our Take: "I agree with the analyst here, the recent dip in the biotech sector has created a good entry point into this one and a few others. Anything under $35 looks good. If using options, selling some puts is also a good way to play this." $IOVA, Iovance Biotherapeutics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so)! Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .